Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide in Moderately Active Crohn's Disease
NCT00072839Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2003
- Primary completion
- Jul 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of teduglutide in Crohn's disease (4 arms), sponsored by Takeda. Primary endpoint: Percentage of subjects who respond to treatment at 8 weeks. Started Nov 2003; status: completed.
02
Drugs
teduglutide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00072839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072839.